120O Pembrolizumab (Pembro) with or without lenvatinib (Lenva) in first-line metastatic NSCLC with PD-L1 TPS ≥1% (LEAP-007): A phase III, randomized, double-blind study

James Chih‐Hsin Yang, Tibor Csőszi, Emmanuel de la Mora Jimenez et al.|Annals of Oncology|2021

Cited by 20